Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
An update from Innate Pharma SA ( (FR:IPH) ) is now available.
On February 17, 2025, Innate Pharma announced that the U.S. FDA granted Breakthrough Therapy Designation to lacutamab for treating relapsed or refractory Sézary syndrome. This designation, based on positive Phase 2 TELLOMAK trial results, is aimed at accelerating the drug’s development. The designation signifies a critical advancement for lacutamab, which previously received Fast Track and PRIME designations. It highlights the drug’s potential to address high unmet medical needs in Sézary syndrome, aligning with Innate Pharma’s strategic efforts to improve patient care in cutaneous T-cell lymphomas.
More about Innate Pharma SA
Innate Pharma S.A. is a global, clinical-stage biotechnology company focused on developing immunotherapies for cancer patients. The company uses three therapeutic approaches: multi-specific NK Cell Engagers via its AN-KET® platform, Antibody Drug Conjugates (ADC), and monoclonal antibodies (mAbs). Innate Pharma collaborates with biopharmaceutical companies such as Sanofi and AstraZeneca to accelerate innovation for patient benefit.
Average Trading Volume: 875
Technical Sentiment Consensus Rating: Hold
Current Market Cap: $183.3M
Find detailed analytics on IPH stock on TipRanks’ Stock Analysis page.
